Higher Plasma Fractalkine Is Associated With Better 6-Month Outcome From Ischemic Stroke | Zendy

Megan Donohue | Zendy; Kevin C. Cain | Zendy; Dannielle Zierath | Zendy; Dean Shibata | Zendy; Patricia Tanzi | Zendy; Kyra J. Becker | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Higher Plasma Fractalkine Is Associated With Better 6-Month Outcome From Ischemic Stroke

Author(s) -

Megan Donohue,

Kevin C. Cain,

Dannielle Zierath,

Dean Shibata,

Patricia Tanzi,

Kyra J. Becker

Publication year - 2012

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.112.657411

Subject(s) - cx3cl1 , medicine , stroke (engine) , inflammation , chemokine , neuroprotection , ischemic stroke , immunology , cardiology , ischemia , chemokine receptor , mechanical engineering , engineering

Fractalkine (CX3CL1) is a unique chemokine that is constitutively expressed on neurons where it serves as an adhesion molecule for lymphocytes and monocytes. CX3CL1 may also be cleaved from the surface of these cells and enter the circulation to act as a traditional chemokine. CX3CL1 could thus influence the inflammatory response after stroke. We hypothesized that patients with higher plasma CX3CL1 after stroke would have a more robust inflammatory response and experience worse outcome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research